ArticleAccounts of chemical research2009
Bioresponsive, cell-penetrating, and multimeric MR contrast agents.
Article in Accounts of chemical research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 316 citations in OpenAlex.
- Inner- and Second-Sphere Interactions of Co(II) and Fe(II) Parashift Agents with Lactate, Trifluorolactate, and Fluoride.Inorganic chemistry · 2026Article
- Octahedral Coordination Cages of Co(II) and Ni(II): Enhanced Probe Signal Through Symmetry.Inorganic chemistry · 2026Article
- Gadolinium Nanoparticles: Emerging Platforms Beyond Imaging for Drug Delivery and Theranostics.Pharmaceutics · 2026Review
- Convergent Evolution: Self-Assembly of Small Molecule, Polymeric, and Inorganic Contrast Agents toward Advanced MRI.Journal of the American Chemical Society · 2025Review
- Applications of nanomaterials in head and neck squamous cell carcinoma: current progress and perspectives.Discover nano · 2025Review
- Effect of the Compartmentalization Into Liposome's Cavity on the Relaxation Times of FNMR in biomedicine · 2025Article
- Novel non‑metal‑based contrast agents for MR imaging: Emerging approaches and clinical perspectives (Review).International journal of oncology · 2025Review
- LnDOTA Releasing Probes for Luminescence and Magnetic Resonance Imaging.Inorganic chemistry · 2025Article
- Article
- Macrocyclic complexes of Fe(III) with mixed hydroxypropyl and phenolate or amide pendants as TDalton transactions (Cambridge, England : 2003) · 2024Article
- Liposomal MRI probes containing encapsulated or amphiphilic Fe(III) coordination complexes.Biomaterials science · 2023Article
- Fluorinated hydrogel nanoparticles with regulable fluorine contents andRSC advances · 2023Article
- Two-photon excited luminescence of structural light enhancement in subwavelength SiODiscover nano · 2023Article
- Energy loss function of samarium.Scientific reports · 2023Article
- Unprecedented Relaxivity Gap in pH-Responsive FeAngewandte Chemie (International ed. in English) · 2023Article
- Functionalized Carbon Nanoparticles as Theranostic Agents and Their Future Clinical Utility in Oncology.Bioengineering (Basel, Switzerland) · 2023Review
- c-Met-TargetingInternational journal of nanomedicine · 2023Article
- MRI Contrast Agents in Glycobiology.Molecules (Basel, Switzerland) · 2022Review
- Magnetic, biocompatible FeCOJournal of nanobiotechnology · 2022Article
- Metal-Organic Polyhedron with Four Fe(III) Centers Producing Enhanced TInorganic chemistry · 2022Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Magnetic resonance imaging (MRI) has become increasingly popular in experimental molecular imaging and clinical radiology because it is non-invasive and capable of producing three-dimensional representations of opaque organisms with high spatial and temporal resolution. Approximately 35% of all clinical MR scans utilize contrast media, however a primary limitation of MR imaging is the sensitivity of contrast agents that require high concentrations (0.1-0.6 mM). A number of strategies have been employed to amplify the observed in vivo signal of MR contrast agents. Approaches include attachment of Gd(III) chelates to polymers, proteins and particles, encapsulation into micelles and caged structures, and targeting to receptors. While each of these approaches has yielded significant increases in the relaxivity of MR contrast agents (and therefore sensitivity), all of these classes of complexes possess intrinsic background signal and function solely as anatomical reporters. In order to reduce the background signal and simultaneously create probes that are modulated by biochemical processes, caged complexes were designed to coordinatively saturate the paramagnetic ion. Coupled with amplification strategies, these agents represent a means to selectively modulate the observed MR signal and function as in vivo biochemical reporters. For example, to create an in vivo MR assay of enzymatic activities and secondary messengers, agents have been designed and synthesized with removable protection groups that largely prevent access of water to a paramagnetic center. By limiting the access of bulk water (q-modulation) the unprocessed agent is designed to be an ineffective contrast agent, and hence serves as a reliable marker for regions of enzyme activity or the presence of secondary messengers. Further, we have focused on designing multimodal contrast agents that are simultaneously detectable by more than one imaging technique. For example, attaching an optical probe to a MR contrast agent provides the means to detect the probe in a whole animal and subsequently validate the results by histological methods. Finally, we describe strategies for signal amplification, and cell delivery vehicles attached to imaging probes for in vivo long-term fate mapping experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.